Who is sponsoring NCT03900117?

NCT03900117 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT03900117?

Interventions in NCT03900117: split-course radiotherapy, concurrent chemotherapy.

What condition does NCT03900117 study?

NCT03900117 studies Non-small Cell Lung Cancer.

Is NCT03900117 still recruiting?

NCT03900117 is currently completed. Last updated 27 October 2022.

Last reviewed 2022-10-27 · How we verify

NCT03900117

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC

Completed Phase 2 Last updated 27 October 2022

What this trial tests

Phase 2 trial testing split-course radiotherapy in Non-small Cell Lung Cancer in 77 participants. Completed in 20 June 2022.

Timeline

1 March 2019

Primary endpoint
20 June 2022

20 June 2022

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	77
Start date	1 March 2019
Primary completion	20 June 2022
Estimated completion	20 June 2022
Sites	1 location across China

Drugs / interventions tested

split-course radiotherapy
concurrent chemotherapy — full drug profile →

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is to assess the safety and efficacy of hypofractionated radiotherapy followed by hypo-boost combined with concurrent weekly chemotherapy in unresectable LA-NSCLC patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Correlation of K<sup>trans</sup> derived from dynamic contrast-enhanced MRI with treatment response and survival in locally advanced NSCLC patients undergoing induction immunochemotherapy and concurrent chemoradiotherapy.
Wang D, Liu S, Fu J, Zhang P, et al · · 2024 · cited 5× · PMID 38910009 · DOI 10.1136/jitc-2023-008574
Early Nutritional Intervention in Patients with Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: A Phase II Prospective Study.
Liu F, Luo Q, Xi Y, Zhang P, et al · · 2025 · cited 1× · PMID 40284252 · DOI 10.3390/nu17081389
Comparing the outcomes of MR-based versus CT-based tumor delineation in locally advanced non-small cell lung cancer treated with hypo-fractionated radiotherapy and concurrent chemotherapy.
Zhang P, Ding S, Peng K, He H, et al · · 2024 · cited 1× · PMID 39670014 · DOI 10.21037/tlcr-24-341

Verify or expand the search:

Other trials of split-course radiotherapy

Trials testing the same drug.

NCT04212052 — Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer · Phase 2 · completed
NCT03659578 — Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer · Phase 2 · completed

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03900117 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 27 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03900117.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing